文献速递心力衰竭与心肌病

MOMENTUM 3试验6个月时HM3与HMII的血液相容性相关结局

Hemocompatibility-Related Outcomes in the MOMENTUM 3 Trial at 6 Months: A Randomized Controlled Study of a Fully Magnetically Levitated Pump in Advanced Heart Failure.
PubMed 文献 · Circulation · 2017-04-06

MOMENTUM 3试验短期队列(6个月随访)的二次分析,比较全磁悬浮HM3与HMII左心室辅助装置在289例晚期心衰患者中的血液相容性相关不良事件。

要点

  • HM3组6个月无HRAE生存率69%,HMII组55%。
  • HM3组需再次手术的泵血栓评分为0分 vs HMII组36分(P<0.001)。
  • HM3组非致残性卒中评分为6分 vs HMII组24分(P=0.026)。

核心结论

  • 在MOMENTUM 3试验的二次分析中,HM3左心室辅助装置在6个月时较HMII表现出更高的无血液相容性相关不良事件生存率。

研究设计与样本

  • MOMENTUM 3试验短期队列(6个月随访)的二次终点分析,比较HM3与HMII左心室辅助装置,as-treated队列共289例(HM3组151例,HMII组138例)。

主要发现

  • 需再次手术的泵血栓评分:HM3组0分 vs HMII组36分(P<0.001)。
  • 药物管理的泵血栓评分:HM3组0分 vs HMII组5分(P=0.02)。
  • 非致残性卒中评分:HM3组6分 vs HMII组24分(P=0.026)。

关键数值与推荐

  • 原文未报告指南或共识推荐。

临床怎么用

  • 原文未报告临床实践指导。

局限性

  • 原文未述局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The HeartMate 3 (HM3) Left Ventricular Assist System (LVAS) (Abbott) is a centrifugal, fully magnetically levitated, continuous-flow blood pump engineered to enhance hemocompatibility and reduce shear stress on blood components. The MOMENTUM 3 trial (Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy With HeartMate 3) compares the HM3 LVAS with the HeartMate II (HMII) LVAS (Abbott) in advanced heart failure refractory to medical management, irrespective of therapeutic intention (bridge to transplant versus destination therapy). This investigation reported its primary outcome in the short-term cohort (n=294; 6-month follow-up), demonstrating superiority of the HM3 for the trial primary end point (survival free of a disabling stroke or reoperation to replace the pump for malfunction), driven by a reduced need for reoperations. The aim of this analysis was to evaluate the aggregate of hemocompatibility-related clinical adverse events (HRAEs) between the 2 LVAS. METHODS: We conducted a secondary end point evaluation of HRAE (survival free of any nonsurgical bleeding, thromboembolic event, pump thrombosis, or neurological event) in the short-term cohort (as-treated cohort n=289) at 6 months. The net burden of HRAE was also assessed by using a previously described hemocompatibility score, which uses 4 escalating tiers of hierarchal severity to derive a total score for events encountered during the entire follow-up experience for each patient. RESULTS: In 289 patients in the as-treated group (151 the HM3 and 138 the HMII), survival free of any HRAE was achieved in 69% of the HM3 group and in 55% of the HMII group (hazard ratio, 0.62; confidence interval, 0.42-0.91; P=0.012). Using the hemocompatibility score, the HM3 group demonstrated less pump thrombosis requiring reoperation (0 versus 36 points, P<0.001) or medically managed pump thrombosis (0 versus 5 points, P=0.02), and fewer nondisabling strokes (6 versus 24 points, P=0.026) than the control HMII LVAS. The net hemocompatibility score in the HM3 in comparison with the HMII patients was 101 (0.67±1.50 points/patient) versus 137 (0.99±1.79 points/patient) (odds ratio, 0.64; confidence interval, 0.39-1.03; P=0.065). CONCLUSIONS: In this secondary analysis of the MOMENTUM 3 trial, the HM3 LVAS demonstrated greater freedom from HRAEs in comparison with the HMII LVAS at 6 months. CLINICAL TRIAL REGISTRATION: URL: http://clinicaltrials.gov. Unique identifier: NCT02224755.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Uriel N, Colombo PC, Cleveland JC, et al. Hemocompatibility-Related Outcomes in the MOMENTUM 3 Trial at 6 Months: A Randomized Controlled Study of a Fully Magnetically Levitated Pump in Advanced Heart Failure. Circulation. 2017. PMID: 28385948. doi:10.1161/CIRCULATIONAHA.117.028303

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。